Modality
Multispecific
MOA
MDM2i
Target
FGFR
Pathway
Tau
Melanoma
Development Pipeline
Preclinical
~May 2022
→ ~Aug 2023
Phase 1
~Nov 2023
→ ~Feb 2025
Phase 2
May 2025
→ Dec 2031
Phase 2Current
NCT03699652
131 pts·Melanoma
2025-05→2029-08·Completed
NCT05799859
1,367 pts·Melanoma
2025-05→2031-12·Terminated
1,498 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-08-273.4y awayPh3 Readout· Melanoma
2031-12-095.7y awayPh3 Readout· Melanoma
Trial Timeline
Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2/3
Complet…
P2/3
Termina…
Catalysts
Ph3 Readout
2029-08-27 · 3.4y away
Melanoma
Ph3 Readout
2031-12-09 · 5.7y away
Melanoma
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03699652 | Phase 2/3 | Melanoma | Completed | 131 | CR |
| NCT05799859 | Phase 2/3 | Melanoma | Terminated | 1367 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| AMG-415 | Amgen | Phase 1 | CDK2 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| Rimasertib | Exelixis | Phase 3 | B7-H3 |